Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline S Copeland

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Addiction (Abingdon, England)|January 24, 2025
Commentary on Craft et al.: Drug contaminants and substitutions in illicit vapes represent a major health riskCaroline S Copeland
Neuronal Signaling|December 23, 2022
The role of thalamic group II mGlu receptors in health and diseaseCaroline S Copeland, Thomas E Salt
The International Journal on Drug Policy|August 31, 2025
Comparison of Office for National Statistics (ONS) and National Programme on Substance Use Mortality (NPSUM) data suggests that opioid-related deaths in England & Wales have been systematically underestimatedShuoqi Chen, David Mais, Caroline S Copeland
British Journal of Clinical Pharmacology|March 17, 2026
Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024Eman Mshari, Caroline S Copeland, Georgia C Richards
Frontiers in Pharmacology|February 16, 2026
Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022)Kirsten L Rock, Ric Treble, Caroline S Copeland
British Journal of Clinical Pharmacology|October 31, 2019
A deadly trend in fentanyl fatalities (England, 1998-2017)Hugh Claridge, Bryn D Williams, Caroline S Copeland
British Journal of Clinical Pharmacology|March 17, 2021
Antihistamine-related deaths in England: Are the high safety profiles of antihistamines leading to their unsafe use?Princess J Oyekan, Hayley C Gorton, Caroline S Copeland
BMJ (Clinical Research Ed.)|February 3, 2026
Ketamine: reclassification alone will not reduce harmsAdam R Winstock, David J Nutt, Caroline S Copeland
Addiction (Abingdon, England)|October 12, 2023
An evaluation of naloxone transit for opioid overdose using drones: A case study using real-world coroner dataPaul G Royall, Patrick Courtney, Christine Goodair, et al.
Journal of Psychopharmacology (Oxford, England)|September 29, 2025
Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999-2024: An update report to inform the reclassification debateJade Pullen, John M Corkery, Rebecca McKnight, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Addiction (Abingdon, England)|January 24, 2025
Commentary on Craft et al.: Drug contaminants and substitutions in illicit vapes represent a major health riskCaroline S Copeland
Neuronal Signaling|December 23, 2022
The role of thalamic group II mGlu receptors in health and diseaseCaroline S Copeland, Thomas E Salt
The International Journal on Drug Policy|August 31, 2025
Comparison of Office for National Statistics (ONS) and National Programme on Substance Use Mortality (NPSUM) data suggests that opioid-related deaths in England & Wales have been systematically underestimatedShuoqi Chen, David Mais, Caroline S Copeland
British Journal of Clinical Pharmacology|March 17, 2026
Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024Eman Mshari, Caroline S Copeland, Georgia C Richards
Frontiers in Pharmacology|February 16, 2026
Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022)Kirsten L Rock, Ric Treble, Caroline S Copeland
British Journal of Clinical Pharmacology|October 31, 2019
A deadly trend in fentanyl fatalities (England, 1998-2017)Hugh Claridge, Bryn D Williams, Caroline S Copeland
British Journal of Clinical Pharmacology|March 17, 2021
Antihistamine-related deaths in England: Are the high safety profiles of antihistamines leading to their unsafe use?Princess J Oyekan, Hayley C Gorton, Caroline S Copeland
BMJ (Clinical Research Ed.)|February 3, 2026
Ketamine: reclassification alone will not reduce harmsAdam R Winstock, David J Nutt, Caroline S Copeland
Addiction (Abingdon, England)|October 12, 2023
An evaluation of naloxone transit for opioid overdose using drones: A case study using real-world coroner dataPaul G Royall, Patrick Courtney, Christine Goodair, et al.
Journal of Psychopharmacology (Oxford, England)|September 29, 2025
Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999-2024: An update report to inform the reclassification debateJade Pullen, John M Corkery, Rebecca McKnight, et al.
Pageof 5